A prospective cohort study assessing the rates of antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine among Kidney transplant recipients, and to identify factors associated with reduced immunogenicity
Latest Information Update: 02 Sep 2021
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Pharmacodynamics
- 02 Sep 2021 New trial record
- 01 Aug 2021 Results published in the Clinical Microbiology and Infection